Company Index
BeiGene
BeiGene
NEWS
Hiring Ernst & Young in the U.S. may help but won’t work without a bilateral Sino-American accord on audit documents
Apr.8 2022 04:59 AM
With listing on STAR Market, loss-making cancer-drug developer would be the first Chinese biotech to trade shares on the mainland and in Hong Kong and New York
Nov.17 2021 05:11 AM
Eleven-year-old cancer-focused Chinese biotech turned its first profit this year after three of its drugs made China’s National Reimbursement Drug List
Jun.29 2021 06:18 AM
May.10 2021 18:28 PM
Dec.3 2020 18:17 PM
Beijing-based BeiGene will take over commercialization of three cancer medicines from American biopharmaceutical giant in China as part of deal, and work to commercialize 20 more
Nov.1 2019 18:25 PM
Nov.1 2019 10:16 AM
Top 15 listings by Chinese firms have raised $28.7 billion so far this year, led by China Tower this week
Aug.10 2018 17:18 PM
After lackluster BeiGene IPO, analysts argue share prices will rise when more products hit market
Aug.8 2018 18:45 PM
Hong Kong IPO could raise nearly $1 billion, complementing drug developer’s current Nasdaq listing
Jul.30 2018 18:47 PM
U.S. biopharmaceutical firm plans to hold 5.9% of cancer-drug developer to market new treatments in Europe and America
Jul.7 2017 18:44 PM
- Jun 16, 2025 02:54 PM
- Jun 16, 2025 02:53 PM
- Jun 16, 2025 02:52 PM
MOST POPULAR
- 1In Depth: A Lost Masterpiece’s Return Exposes Scandal at a Top Chinese Museum
- 2China Launches $14 Billion State Fund to Back Strategic Tech Industries
- 3Offshore Yuan Breaches 7.0 Per Dollar to Hit 15-Month High
- 4Weekend Long Read: When China Speed Meets Brazil Rhythm
- 5Cover Story: China’s AI Titans Escalate Battle for Control of Digital Gateways
Sign in with Google
Sign in with Facebook
Sign in with 财新